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2Abstract 
 
Headache is a common symptom caused by a wide variety of diseases. Primary 
headaches include migraine, cluster headache, tension-type headache and other less 
common diseases. It is important to differentiate these headaches from secondary 
headaches caused by vascular, neoplastic, infectious, metabolic and toxic disorders. Most 
primary headaches have a genetic basis, with environmental factors acting as triggers. 
Recent advances in basic research resulted in the development of more specific and 
effective therapies. Medication overuse headache is a very common cause of chronic 
daily headache. Detoxification from the offending drug is essential for headache 
improvement. Cervicogenic headache is common and needs to be diagnosed correctly 
since it may require specific therapy. Nerve blocks are useful for some patients with 
primary, as well as secondary, headaches.  
3Introduction 
 
Headache is a very common symptom, with a life time prevalence approaching 100%. 
Most headaches are caused by benign (yet sometimes incapacitating) diseases like 
migraine and tension-type headache. Life-threatening causes of headache are less 
frequent but important to recognize. Recent progress in the understanding of headache 
mechanisms has led to the development of new and effective treatments for primary 
headaches.   
 
In this review we will discuss the clinical features and treatment of common primary 
headaches, as well as of secondary headaches that are of special interest to the 
anesthesiologist. We will also discuss symptoms and signs that should prompt a search 
for a potentially life-threatening cause of headache. Finally, we review peripheral nerve 
blocks as a treatment for headaches.  
 
Primary headaches 
 
Primary headaches are a disorder unto themselves. They are defined by the characteristics 
of the headache and its associated symptoms.  
 
Migraine 
 
4Migraine is a neurovascular disorder characterized by episodes of headache accompanied 
by various combinations of gastrointestinal symptoms, autonomic nervous system 
dysfunction and, in some patients, an aura consisting of transient neurologic symptoms 
[1,2].  
 
Epidemiology 
 
Migraine is a very common disorder with a one-year prevalence of 12% in the adult 
population (18% in women and 6% in men) and 4% in children in the US and Western 
Europe [3]. Migraine prevalence is highest between the ages of 25 and 55 years, which 
are the years of peak productivity [4].  This age distribution, along with the high 
disability caused by migraine in a significant proportion of patients, explains the high 
economic impact of the disease. The World Health Organization (WHO) rates migraine 
as one of the most disabling chronic diseases [5] . 
 
Clinical features 
 
The two major subtypes of migraine are migraine without aura (MO) and migraine with 
aura (MA) [6]. Patients with both MO and MA may experience premonitory symptoms 
several hours to days before the attack. These include fatigue, depression, cognitive 
dysfunction and food craving [7].  
 
5MO is the most common subtype of migraine. It typically manifests as recurrent episodes 
of moderate to severe unilateral headache which is throbbing in quality and aggravated 
by physical activity. The headache may be associated with nausea or vomiting and/or 
photophobia and phonophobia. Migraine headache, however, may be non-throbbing or 
bilateral [1]. According to the International Headache Society (IHS) criteria, these 
episodes should last 4-72 hours (Appendix 1). A migraine attack that lasts more than 72 
hours is defined as status migrainosus.  
 
MA manifests as attacks of headache similar to those of MO that are preceded by 
reversible focal neurologic symptoms called aura (Appendix 2). The aura develops 
gradually over 5-20 minutes and usually lasts for less than 60 minutes. The most common 
type of aura is visual, manifesting as scotoma (partial loss of vision), photopsia 
(unformed flashes of light) or fortification spectra (zig-zag lines). Less commonly, aura 
may be sensory (paresthesias), motor (focal weakness) or involve language function. 
Usually the aura precede the headache, but occasionally it appears simultaneously with it. 
In other, less common, cases the aura may occur without the headache.  
 
Migraine attacks can occur from once in several months to several times a week and can 
last from few hours to several days. Headache severity ranges from moderate to 
completely incapacitating.  Following the attack the patient may feel tired, irritable and 
listless.  
 
Pathophysiology 
6Migraine is currently considered a primary brain disorder with secondary involvement of 
meningeal blood vessels [2,8]. There is evidence for a generator of migraine attacks in 
the upper brainstem, probably involving nuclei that modulate craniovascular pain 
afferents [9]. During an attack trigeminal sensory neurons are activated and release 
substance P, calcitonin gene related peptide (CGRP) and neurokinin A. This results in 
neurogenic inflammation, meningeal blood vessel dilatation and plasma protein 
extravasation. Some of these processes are mediated by serotonin, released from 
trigeminal nerve endings adjacent to meningeal blood vessels [10]. There is also evidence 
for sensitization of neurons in the trigeminal nucleus caudalis (TNC) in animal models of 
headache that may apply to migraine [11]. Clinically, during migraine attacks patients 
may experience cutaneous allodynia, probably related to central sensitization [12].  
Migraine aura appears to be related to the phenomenon of cortical spreading depression 
described by Leão [13]. Aura is associated with neuronal events which reduce cerebral 
activity and with a wave of spreading oligemia that advances across the cerebral cortex 
from the occipital area forward at a characteristic rate of 2-3 mm/min. This oligemia is 
preceded by a short phase of hyperemia due to CNS activation and is not confined to 
specific blood vessel territories [14].  
There is a known genetic predisposition to migraine. The relative risk of first degree 
relatives of migraine patients to suffer from the disease is 1.9 for MO and 3.8 for MA 
[15].  
 
Management 
7Initial approach to the headache patient 
 
The management of migraine begins with making a correct diagnosis. Laboratory and 
imaging studies should be done in the appropriate cases to exclude secondary causes of 
headache [16]. Symptoms, signs and clinical settings that should raise suspicion of a 
worrisome underlying disease include (Table 1): 
 
1. New onset of headache in a patient older than 50 years.  
2. The sudden onset of headache. 
3. The occurrence of the worst headache ever.  
4. A progressively-worsening headache. 
5. Headache in a patient with cancer or AIDS. 
6. Headache with fever or rash. 
7. Headache with papilledema.  
8. Headache with focal neurologic signs. 
 
In any of the above cases, a neurologic consultation should be obtained and the proper 
tests (e.g. neuroimaging, lumbar puncture, ESR) performed. Neuroimaging is not usually 
recommended for patients with a typical clinical picture of migraine and a normal 
neurologic examination [17].  
 
Once the diagnosis of migraine is established, it should be explained to the patient and a 
treatment plan developed. Triggers for migraine attacks, such as emotional or mental 
8stress, poor sleep patterns, skipped meals and hormonal changes in women, should be 
addressed and corrected or avoided if possible.  
 
Drug therapy 
 
Migraine pharmacotherapy may be acute, to reverse the symptoms of the acute attack or 
preventive, to reduce the frequency, severity and duration of attacks.  
 
Treatment of the acute attack 
 
Acute migraine treatment can be divided into non-specific (drugs that are used to treat 
various pain disorders) and migraine-specific drugs. The non-specific drugs include 
acetaminophen, aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), opiates and 
anti-emetic drugs. The migraine-specific drugs include the ergots and the 5HT 1B/1D 
agonists known as the triptans.  
 
Several principles should be followed in acute migraine treatment. 1. The drug should be 
taken as early as possible into the attack. This will increase treatment efficacy and 
accelerate the clinical response [18] [19].  2. The dose should be adequate (e.g. 1000 mg 
of acetaminophen;s 500-1000 mg of naproxen). 3. The route of administration should be 
appropriate. For patients with severe nausea or vomiting a parenteral route is preferred. 4. 
The number of treatments should be limited to 2-3/week to avoid analgesic-overuse 
headache. The choice of drug and route of administration for the individual patient 
9depend on the severity of the attack, its rate of evolvement, associated symptoms and 
coexisting diseases.  
 
Non-specific drugs 
 
NSAIDs and other simple analgesics are effective for some migraineurs [1]. Opioid use 
should be minimized due to the potential risks of drug overuse with resultant headache 
exacerbation [20]. It has been recently suggested that opioid therapy should not be the 
first line treatment for acute headache in an emergency department setting [21].  An 
analysis of 160 refractory headache patients treated with daily scheduled opioids (DSO) 
in a referral headache center was recently performed  [22].  Only 26% of the patients had 
>50% headache improvement. Despite careful screening and patient selection, 
problematic drug behavior occurred in 50 % of patients, the most common of which was 
dose violation. The authors concluded that opioid therapy may provide significant long 
term relief to selected patients, although most subjects did not improve with this 
treatment.  
Several anti-emetics and neuroleptics are effective for acute migraine treatment. 
Prochlorperazine, chlorpromazine, promethazine or metoclopramide can be used for both 
migraine headache and associated nausea and vomiting [23-25]. Droperidol, a potent 
dopamine receptor antagonist, has recently been found effective for acute migraine 
treatment at a dose of 2.75 mg intramuscularly [26]. Droperidol is associated with a dose-
dependent prolongation of the QT interval. This effect may be seen within 10 minutes of 
drug administration [27]. There is a black box warning for droperidol (Inapsine) stating 
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that : “cases of QT prolongation and/or torsades de pointes have been reported in patients 
receiving inapsine at doses at or below recommended doses. Some cases occurred in 
patients with no known risk factors for QT prolongation and some cases have been fatal” 
[27].  QT interval, as well as calcium and potassium blood levels should be measured 
before treatment [28].  
 
Migraine-specific drugs 
 
Ergot derivatives 
 
Ergots have been used for migraine treatment for over 50 years [29]. Since the 
introduction of the more pharmacologically-specific triptans, the justification for their use 
has decreased. They remain, however, useful for some patients with prolonged attacks or 
high headache recurrence rates. Dihydroergotamine (DHE) has fewer adverse events and 
is less likely to produce rebound headache compared with ergotamine. It can be given 
intranasally or intramuscularly in an out patient setting. Repetitive intravenous DHE is 
the mainstay of treatment for refractory migraine in an inpatient setting [30].    
 
Triptans 
 
The development of the triptans and their introduction to clinical use in the early 1990s 
have dramatically changed acute migraine treatment [2,28]. The triptans have a more 
specific pharmacologic profile than the ergots and their efficacy has been established in 
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well-designed clinical trials. There are currently seven triptans available for acute 
migraine treatment: sumatriptan, zolmitriptan, naratriptan, rizatriptan, almotriptan, 
frovatriptan and eletriptan (Table 2). Triptans are 5HT 1B/1D receptor agonists. They 
relieve symptoms of acute migraine attack by several mechanisms: vasoconstriction of 
meningeal vessels, inhibition of primary trigeminal afferent fibers and inhibition of 
second-order neurons in the TNC [2].  The triptans differ in their pharmacokinetics, 
available formulations and, to some extent, efficacy and tolerability. All triptans are 
available in an oral formulation. Some (rizatriptan, zolmitriptan) are also available in an 
orally-dissolved formulation and some as a nasal spray (sumatriptan, zolmitriptan). 
Sumatriptan can also be injected subcutaneously.  The triptans are effective and well-
tolerated for acute migraine treatment. Common side effects include dizziness, 
paresthesias, warmth sensation and chest pressure, which is probably non-cardiac in 
origin. Although 5-HT 1B receptors have been found in the coronary circulation, the 
triptans have proved to be very safe drugs with rare reports of adverse cardiovascular 
events [31]. Still, they are contraindicated in patients with ischemic heart disease, 
cerebrovascular disease, uncontrolled hypertension and hemiplegic or basilar migraine.  
 
Preventive treatment 
 
Preventive drug therapy is given to reduce attack frequency, duration and severity [32]. It 
may also render migraine attacks more responsive to acute treatment. Indications for 
starting preventive treatment include: migraine that significantly interferes with the 
patient’s daily routine despite acute treatment; failure of-, contraindication to-, or 
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troublesome adverse events from acute medications; acute medication overuse; very 
frequent headaches (>2/week); patient preference; hemiplegic migraine or attacks with a risk 
of permanent neurologic injury [33]. Drugs that are used for migraine prevention include the 
-adrenergic blockers, antidepressants, anticonvulsants, calcium channel blockers, serotonin 
antagonists and NSAIDs (Table 3) [1]. The choice of a preventive drug is based on efficacy, 
prior patient exposure, adverse-event profile, comorbidity and concomitant drug therapy. In 
general, preventive drugs are started at a low dose that is increased gradually while 
monitoring tolerability and efficacy. Patients should be advised that a full therapeutic 
response may take several weeks to months to occur.   
 
Recently, Botulinum toxin type A (BTX-A, Botox®) was found to be effective for migraine 
prophylaxis [28,34]. The toxin is injected intramuscularly at different sites in the head or 
neck. Common injection sites are the glabellar, frontalis, and temporalis muscles. Treatment 
with BTX-A is safe, well-tolerated and has a long duration of action (of up to four months). 
It is particularly appealing for patients who have poor compliance, or are intolerant, to daily 
drug treatment. Side effects are transient and include blepharoptosis, diplopia and injection 
site weakness. Non-pharmacologic preventive strategies include relaxation training, 
biofeedback and cognitive-behavioral therapy [35].  
 
Cluster headache 
 
Cluster headache (CH) is the most painful of the primary headaches [36,37]. It is 
characterized by episodes of severe, strictly unilateral headache associated with 
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symptoms and signs of cranial parasympathetic hyperactivity and sympathetic 
dysfunction. 
 
Epidemiology 
 
CH is less common than migraine, with an estimated prevalence of 0.4% [36]. In contrast 
to migraine, it is more common in men than in women, with a gender ratio of 
approximately 5:1. Recent studies, however, suggest that this ratio is decreasing [38]. The 
disease onset is usually in the third decade.  
 
Clinical features 
 
The hallmark of CH is its periodicity. In most patients attacks occur during specific times 
called cluster periods. These periods last for several weeks to months and are separated 
by remission periods that may last several weeks to many years [36]. In many patients 
cluster periods occur with striking regularity at the same time of the year. A minority 
(10%) of patients have only short remission periods (lasting less than one month) or none 
at all. They are classified as having chronic (as opposed to episodic) CH.  
During a cluster period the attack frequency ranges from one every other day to eight per 
day. CH attack is characterized by a rapidly developing, severe, unilateral pain in the 
periorbital, temporal or frontal area. The pain usually lasts 45-90 minutes and is 
associated with symptoms and signs of autonomic dysfunction (conjunctival injection, 
lacrimation, nasal congestion, rhinorrhea, miosis, ptosis) ipsilateral to the pain. Unlike the 
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migraine patient, the CH patient is restless during an attack. Attacks may occur at any 
time during the day, many times at the same hour for the individual patient. In patients 
with episodic, but not chronic, CH, a common time for an attack is at night, coinciding 
with the first REM sleep period [39]. The IHS diagnostic criteria for CH are listed in 
Appendix 3.  
 
Pathophysiology 
 
CH was previously though to be a “vascular headache”. More recent studies, however, 
show evidence of activation of the trigeminovascular system in CH [36]. The striking 
periodicity of CH attacks has led to the theory of a central generator for CH. Recent 
evidence for this theory comes from positron emission tomography (PET) studies that 
show activation of the ipsilateral posterior ventral hypothalamus during CH attack [40].  
 
Management 
 
The management of CH consists of patient support and education, treatment of the acute 
attack and preventive treatment (Table 4) [36]. Treatment options for the acute attack 
include inhalation of 100% oxygen, sumatriptan injections and intravenous DHE. Oxygen 
should be given at a high flow rate (>7 liter/min) via a non-rebreathing mask for at least 
15 minutes. This treatment is very effective, however it is not always readily available. 
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Subcutaneous sumatriptan is very effective for the treatment of acute CH attack, with a 
response rate of over 70%. DHE is best given intravenously for prompt relief of CH 
attack. Since this can not be done at home, this treatment option is less attractive than 
sumatriptan. Intranasal lidocaine is less effective than the above treatments for acute CH, 
but may be used as an adjunctive therapy in severe cases [41].  
 
The preventive treatment of CH is divided into transitional prophylaxis and maintenance 
prophylaxis. Transitional prophylaxis is given at the beginning of a cluster period in an 
attempt to prevent attacks until the maintenance preventive drug is effective. This is 
achieved by either an oral corticosteroid (e.g. prednisone 60 mg/day for three days 
followed by a gradual taper-off over three weeks) or by oral ergotamine 2 mg/day for 2-3 
weeks. Maintenance prophylaxis is given throughout the time of the cluster period. It is 
started in parallel with the transitional prophylaxis and continued thereafter alone. The 
drug of choice for maintenance prophylaxis is verapamil. High doses, of up to 720 
mg/day, are occasionally needed. Other treatment options include lithium carbonate, 
methysergide, valproic acid, topiramate and melatonin. A minority of patients who are 
refractory to medical treatment may need ablative surgical procedures directed at the 
trigeminal nerve root or ganglion [36]. A novel approach to the preventive treatment of 
CH is deep brain stimulation of the posterior-inferior hypothalamus, the area shown to be 
activated during CH attacks [42]. Results with this treatment are encouraging but the 
number of treated patients is still small.  
 
Tension-type headache 
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Tension-type headache (TTH) is the most common type of headache. TTH is divided into 
episodic (<15 days/month) and chronic (O15 days/month) sub-types. In most patients, 
chronic TTH evolves from episodic TTH.  
 
Epidemiology 
 
In a Danish  population-based study the lifetime prevalence of TTH was as high as 78% 
[43]. Many of these patients had short duration or infrequent headaches. Still, 10% had 
headache weekly and 2-3% had it daily. In other studies the prevalence of episodic TTH 
was 32-35% and that of chronic (daily or near daily) TTH – 2.2-2.7% [44] . The 
prevalence of TTH peaks between the ages of 30 and 39 years and, in contrast to 
migraine, there is only a slight female preponderance (M:F ratio of 4:5).   
 
Clinical features 
 
The pain of TTH is typically bilateral, pressing or tightening in quality and of mild to 
moderate intensity. It is not worsened by routine physical activity. There is no nausea, but 
photophobia or phonophobia may be present [6,44]. According to IHS criteria, the pain of 
TTH lasts 30 minutes to seven days. Other symptoms include fatigue, sleep disturbances 
and lightheadedness [45]. There is no aura. The neurologic and physical examination is 
normal except for pericranial muscle tenderness in some patients. The IHS diagnostic 
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criteria for chronic TTH are listed in Appendix 4 (for diagnostic criteria of episodic 
tension-type headache, see reference 6).  
 
Since both migraine and TTH are very common disorders, they may coexist in an 
individual patient. As with all primary headaches, the diagnosis of TTH should be made 
only when secondary causes of headache are not suggested by history or by physical 
examination. When a secondary headache is suggested, it should be excluded by the 
appropriate investigation (see Table 1).  
 
Pathophysiology 
 
Little is known about the pathophysiology of TTH. It is likely that both peripheral and 
central mechanisms play a role. The increased pericranial muscle tenderness found in 
many patients with TTH probably represents activation of peripheral nociceptors [46]. 
Myofascial tenderness was shown to precede the headache and is therefore likely to be 
involved in the pathogenesis [47]. Changes in central processing of sensory information 
are also likely to play a role. This is supported by the observation of decreased threshold 
to pain, thermal and electric stimuli in chronic TTH [48]. There is a higher prevalence of 
depression and anxiety in patients with chronic TTH, compared with the general 
population, but this may be secondary to the pain rather than the cause of it. 
 
Management 
 
18
Since the basic mechanisms are poorly understood, the treatment of TTH is still not 
satisfactory. Management includes pharmacologic and non-pharmacologic treatments. 
For mild to moderate acute episodes, acetaminophen 1000 mg and aspirin (500-1000 mg) 
are effective [49]. NSAIDs were also shown to be effective in relieving pain of acute 
TTH and are recommended for moderate to severe pain. Recommended drugs and doses 
include: ibuprofen 200-400 mg, naproxen 375-550 mg and diclofenac potassium 12.5-25 
mg. Caffeine-containing combination analgesics may be superior to simple analgesics in 
reliving TTH pain. To avoid medication-overuse headache, the patient should be advised 
not to overuse acute medications.  
 
The tricyclic antidepressant amitriptyline is the most widely-used drug in the preventive 
treatment of TTH [50]. Its efficacy has been shown in several well-designed trials and it 
is considered the drug of choice for this indication. The recommended daily dose is 10-75 
mg. The efficacy of the SSRIs in chronic TTH prevention is not well-established. Other 
potential treatments that need further study include the muscle relaxant tizanidine and 
botulinum neurotoxin.  
 
Non pharmacologic treatments for TTH include relaxation training, electromyographic 
biofeedback and cognitive-behavioral therapy. There is well-established evidence for the 
efficacy of these treatment modalities in TTH [51]. Used either as an adjunct or an 
alternative to pharmacologic treatment, they reduce headache frequency, affective 
distress and headache-related disability. These treatments are particularly appealing to 
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patients who do not tolerate, do not respond to or have a contraindication to drug 
treatment.   
 
Medication overuse headache (MOH) 
Patients who suffer from frequent headaches often overuse pain medications [52] . It is 
estimated that 4% of the population suffer from chronic daily headache, defined as 
headache occurring O15 day/month, and medication overuse is by far the most common 
cause of this type of headache[6] [53].  
The concept that pain medication over-use may cause or perpetuate chronic daily 
headache in headache-prone patients has long been recognized [54]. This has been 
previously termed “rebound headache” or “drug-induced headache”. The IHS defined 
this headache as “medication overuse headache” (MOH) and listed separate diagnostic 
criteria for headaches caused by each of the major overused drugs (ergotamine, triptans, 
simple analgesics, opioids and combination analgesics) [6].  
Recently, Zwart et al showed in a prospective study of 32 067 patients that analgesic 
overuse is a predictor of having chronic pain and that the risk was highest for patients 
with migraine [55]. 
 
Making the diagnosis of MOH is extremely important since the primary measure in 
alleviating this type of headache is to stop the intake of the offending drug. Moreover, it 
has been shown that acute pain-medication overuse renders migraine preventive drugs 
less effective or not effective at all [54].  
 
20
In order for a drug to be recognized as a cause of headache, several factors need to be 
considered: treatment frequency, duration, regularity and dose. These parameters are 
different for the various drugs, depending on their propensity to cause headache. In 
general, the treatment frequency required by the IHS is 10-15 days/month, the drug 
should be taken on a regular basis and the duration of treatment should be O3 months.    
Other important criteria in defining a headache as MOH are: 1. the headache has 
developed or markedly worsened during treatment with the drug; and 2. the headache 
resolves or improves within two months of discontinuation of the drug. Limmroth et al 
calculated the mean critical treatment duration until the onset of MOH (MCDO), the 
mean critical monthly intake frequency (MCMIF) and mean critical monthly dosage 
(MCMD) in 98 patients with MOH [56]. They found that MCDO was 1.7, 2.7 and 4.8 
years for triptans, ergots and analgesics, respectively. The MCMIF was lowest for 
triptans (18 doses/month) and highest for analgesics (114 doses/month). They concluded 
that triptan overuse leads to MOH faster and with lower doses compared with ergots and 
analgesics.   
 
Clinical features 
According to IHS definition, MOH should be present in >15 days/month. It 
characteristics vary depending on the type of offending drug. It can be bilateral and 
pressing/ tightening in quality when simple analgesics or ergotamine are used or it can be 
unilateral and pulsating when a triptan is used. Its intensity varies from mild to severe. 
Migraine-associated symptoms may or may not be present.  
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The mechanisms by which an analgesic or an anti-migraine drug cause or exacerbate 
headache are incompletely understood. Continued intake of acute medications may result 
in resetting the pain control mechanisms in susceptible individuals, perhaps by enhancing 
central sensitization or by blocking adaptive antinociceptive changes [57].  
 
Management 
 
The treatment of MOH consists of discontinuation of the offending drug and then starting 
the patient on a new pharmacologic regimen without exceeding the limits of drug dose 
and frequency [58]. Bigal et al studied 456 migraine patients who overused acute 
medications [59]. At one year follow-up, those patients who stopped overusing acute 
medications had a 74% reduction in headache frequency, compared with 17% for those 
who continued overusing them. There was also a significantly greater reduction in 
headache duration and headache intensity in patients who stopped overusing medications 
compared to those who did not.  
During the washout period from the overused drug, headache may temporarily get worse 
before it gets better. This should be explained to the patient. Other withdrawal symptoms, 
e.g. nausea, vomiting, agitation, sleep disturbances and rarely, seizures, may occur. This 
withdrawal period, which last 3-6 weeks, is usually followed by a significant headache 
improvement.  
Detoxification may be done either in an outpatient or an inpatient setting. There are two 
outpatient strategies for this purpose. One is to taper off the offending drug gradually 
over 2-3 weeks, substituting it temporarily for a long acting NSAID (e.g. naproxen 
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sodium) while an effective longer term preventive therapy is established. The other is to 
discontinue the offending drug abruptly, substitute it temporarily for an NSAID, 
prednisone, DHE or a combination of NSAID and tizanidine [58]. An example of such a 
bridging treatment is naproxen sodium 550 mg twice a day for a week which is tapered 
off gradually. When butalbital-containing drugs are discontinued abruptly, low-dose 
phenobarbital (tapering from 60 to 15 mg/day for one week) is given to prevent 
withdrawal symptoms. During detoxification the patient should be given a rescue 
medication for acute headache. Drugs used for this purpose are neuroleptics, anti-nausea 
drugs or opioids (unless the patient is in the process of detoxification from them). When 
out patient detoxification fails or when there is significant medical or psychiatric 
comorbidity, inpatient strategies are used. The most widely used drugs for this purpose is 
repetitive IV DHE with metoclopramide [30]. Alternative treatments used intravenously 
for patients who have contraindication to or can not tolerate DHE, include 
chlorpromazine [60], methylprednisolone [61], valproic acid [62] and lidocaine [63] .   
An important part of management is patient education. The patient should be encouraged 
to limit acute medication use to the recommended frequency, i.e. for simple analgesics- 
<15 days/month and for ergotamine, triptans, opioids and combination analgesics- <10 
days/month.  
 
Secondary headaches 
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Of the many secondary causes of headache, we will discuss cervicogenic headache, 
which is of particular interest to the anesthesiologist. 
 
Cervicogenic headache 
 
Cervicogenic headache (CEH) is a term introduced by Sjaastad in 1983 [64]. It is defined 
as pain perceived in the head whose source lies in the neck [65]. The IHS has accepted 
CEH as a type of secondary headache and included it in its Classification of Headache 
Disorders [6]. In the IHS criteria for CEH diagnosis there is an emphasis on clinical and 
laboratory evidence for a source of pain in the neck and on abolition of headache 
following a diagnostic blockade of the presumed source of pain. It did not provide 
defining criteria for the features of CEH pain or its associated symptoms (Appendix 5). 
The criteria of The Cervicogenic Headache International Study Group also include head 
pain characteristics [66]. 
 
The anatomical basis for the concept of headache resulting from cervical pathology lies 
in neural convergence. Neurons in the dorsal horn of the upper three cervical segments of 
the spinal cord receive overlapping input from  both cervical and trigeminal afferents 
[67]. Thus, any structure innervated by neurons whose central processes reach the upper 
three cervical segments may be a source of headache. Clinical studies support this 
concept. In some patients with headache the pain could be reproduced by stimulation of 
the C2-C3 intervertebral disc. In other patients, complete headache relief was achieved by 
anesthetic block of the lateral atlantoaxial joint [68].  
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Epidemiology and clinical features 
 
The prevalence of CEH is estimated at 0.4%-4.6%. CEH is more common in women 
compared with men and (female to male ratio 4:1) and the mean age is 42.9 [69].    
The hallmark of CEH is clinical evidence for neck involvement including precipitation of 
pain by neck movement or external pressure over the neck or occiput; restriction of neck 
range of motion, and ipsilateral neck, shoulder or arm pain [66].  The pain is typically 
unilateral without side shifts, starting in the neck and spreading anteriorly to the 
ipsilateral orbital, frontal and temporal areas. It is initially episodic but often becomes 
continuous and fluctuating. Pain intensity is usually moderate and it is non-throbbing in 
character. Nausea, vomiting and photo/phonophobia may occur, but are less frequent and 
less intense than in migraine. A history of head or neck trauma is common.  
A positive response to anesthetic block is one of the diagnostic criteria to CEH. These 
include greater occipital nerve (GON), lesser occipital nerve (LON) and C2/C3 facet joint 
blocks. The block should result in elimination or near-elimination of the pain, and the 
analgesic effect should be demonstrated in non-anesthetized areas. Radiologic findings in 
CEH are usually non-specific but may help in identifying a cervical pathology that is a 
potential source of pain (e.g. congenital abnormalities, bone tumors, rheumatoid arthritis, 
ankylosing spondylitis). Cervical spine osteoarthritis has not been demonstrated to be a 
cause of CEH.  
 
Management 
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The approach to a patient with CEH includes a detailed history, physical and neurologic 
examination with an emphasis on signs of cervical pathology (local tenderness, limited 
range of motion and arm weakness, paresthesias or hypoesthesia) and, in some cases, 
imaging studies to exclude lesions that would require specific therapy (e.g. tumor, 
rheumatoid arthritis). Anesthetic blockade of a cervical nerve or joint is recommended to 
support the diagnosis.  
 
The management of CEH includes both  pharmacologic and non-pharmacologic  
components [70].  
 
Pharmacologic treatment has not been evaluated in controlled trials and therefore no 
evidence-based recommendations can be made. Medications are usually not significantly 
effective as the sole therapy, and are used as an adjunct to physical and behavioral 
therapy. Drugs that have been used include the tricyclic antidepressants (amitriptyline, 
nortriptyline), anticonvulsants (valproic acid, carbamazepine, gabapentin, topiramate), 
muscle relaxants (tizanidine, baclofen) and NSAIDs. Drugs from the last two groups can 
be used either for prevention or on an acute basis for pain exacerbation. The other drugs 
are used for prophylaxis. Cervical epidural injections of corticosteroids may be beneficial 
in some patients. Botulinum toxin, injected into cervical muscles can be used but its 
efficacy has not been proven.  
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Physical therapy, an important part of CEH therapy, includes muscle stretching and 
cervical manipulation performed in a gradually progressing manner. Other treatments 
include biofeedback, relaxation techniques and cognitive-behavioral therapy. 
 
Nerve and anesthetic joint blockade are important in CEH, both as a diagnostic and a 
therapeutic tool [71] [70] [72]. Possible sites include the GON, LON, C2/C3 cervical 
spinal nerves and upper cervical zygapophyseal joints. Anthony found that injection of 
depot methylprednisolone to the area of the GON and LON resulted in complete 
headache relief in 169 of 180 patients with CEH [71]. The mean duration of relief was 
23.5 days. When an anesthetic block is effective, longer acting neurolytic procedures 
(e.g. pulsed radiofrequency thermal neurolysis) may be considered. Surgical procedures 
(neurectomy, dorsal rhizotomy, microvascular decompression of nerve roots) are 
reserved for patients with clear evidence of a correctable cervical pathology or who are 
refractory to all other treatment modalities. Nerve stimulation is increasingly used now 
for these purposes and may gradually replace the ablative procedures in the appropriate 
cases.     
 
Nerve blocks for the treatment of headaches 
 
Peripheral nerve blocks have been used to treat headaches for decades [73,74]. The most 
widely used procedure for this purpose is GON block. Other nerve blocks (supraorbital, 
lesser occipital) are occasionally used.   
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The GON is composed of sensory fibers that originate in the C2 and, to a lesser extent, C3
segments of the spinal cord. Its cutaneous sensory distribution is over the posterior part of 
the head, spreading anteriorly to the vertex. It becomes superficial 2.5-5 cm inferolateral 
to the occipital protuberance [75]. There is no standard protocol for GON block 
procedure. A 23 gauge needle is inserted 3.5 cm inferolaterally to the occipital 
protuberance and the nerve is usually infiltrated with a local anesthetic (e.g. of 1% -2% 
lidocaine or 0.5 % bupivacaine) [76]. At times, a corticosteroid (e.g. triamcinolone) is 
added.  
The rationale for GON block comes from the convergence of sensory input to TNC 
neurons from both cervical and trigeminal fibers. This may result in alleviation of pain 
even outside of the GON territory when the nerve is blocked [73].  
Supraorbital nerve (SN) block is performed by inserting the needle at the supraorbital 
notch, which is the point of emergence of this nerve to the epicranial tissue, and 
infiltrating the area with small volumes of the drugs mentioned above.   
 
Despite their widespread clinical use, the number of studies performed to assess the 
efficacy of nerve blocks for headache treatment is small [73,74,77,78]. Caputi and Firetto 
found that 85% of 27 migraine patients responded beneficially to repeated anesthetic 
blocks [73]. They used 0.5-1 cc of bupivacaine 0.5% on alternate days for a maximum of 
ten blocks. The therapeutic effect was maintained for the entire period of observation (six 
months) and the treatment was very well tolerated. In another study, the diagnostic value 
and effects of GON and SN blocks in migraine, TTH and cervicogenic headache  patients 
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were examined in 52 patients [77]. A single injection of 0.5-1.5 cc of lidocaine 2% with 
adrenaline 12.5 µg/ml, was used. GON blockade resulted in pain reduction of 54.5%, 
14% and 6% in the CEH, TTH and migraine groups, respectively. SN blockade resulted 
in corresponding response rates of 28%, 30% and 16%. Gawel and Rothbart examined 
the effect of GON block combined with corticosteroid refractory patients with migraine 
and post-traumatic headache [74]. All patients had been refractory to pharmacologic 
treatment. Seventy two percent of the post-traumatic headache patients and 54% of the 
migraine patients reported being “significantly better” up to six months after the block. 
Peres et al found that 64% of CH patients who were treated with GON block combined 
with a corticosteroid had good or moderate response [78]. Duration, frequency and 
intensity of attacks were significantly lower one week after treatment compared with 
these parameters before treatment. The procedure was very well tolerated.  
Peripheral nerve blocks are safe and easy-to-perform procedures that are beneficial for 
some patients with headaches. They appear to be most effective for cervicogenic 
headache. More studies, however, are needed to evaluate their efficacy in primary 
headaches and to identify the patients who are most likely to benefit from this treatment.  
 
Summary 
 
The successful management of headache depends on arriving at a specific diagnosis and 
not treating the headache as a symptom. It is important to differentiate between primary 
and secondary headaches and to recognize symptoms and signs that raise suspicion of 
life-threatening diseases. In the management of primary headaches, emphasis should be 
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put on life-style alterations and avoidance of triggers to reduce attack frequency and 
severity. Acute pharmacologic treatments should be used at the appropriate dosages and 
time intervals to avoid medication-overuse headache. Using this approach, most headache 
patients can achieve significant symptomatic relief.   
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Table 1: Worrisome symptoms, signs and clinical settings in the patient with 
headache 
 
Abbreviations: IIH - idiopathic intracranial hypertension; AVM - arteriovenous 
malformation; CVT- cortical vein thrombosis; MRV – magnetic resonance venography 
 
Symptom, sign or 
clinical setting 
Differential diagnosis Work-up 
Headache after the age of 
50 
Temporal arteritis; 
Intracranial tumor 
ESR, neroimaging 
Hyperacute headache Subarachnoid hemorrhage; 
Intracerebral hemorrhage 
Neuroimaging, lumbar 
puncture 
Worst headache ever Subarachnoid hemorrhage; 
Meningitis 
Neuroimaging, lumbar 
puncture 
Progressively-worsening 
headache 
Intracranial tumor or other 
space occupying lesion 
Neuroimaging 
Headache in a patient 
with cancer or AIDS 
Chronic or subacute 
meningitis; Meningeal 
carcinomatosis; Brain 
metastases; CNS 
lymphoma; Brain abscess 
Neuroimaging, lumbar 
puncture 
Headache with fever or 
rash 
Meningitis Lumbar puncture, blood 
and CSF serology  
Headache with 
papilledema 
Brain tumor or abscess; 
Dural sinus thrombosis; 
IIH  
Neuroimaging including 
MRV, lumbar puncture 
Headache with focal 
neurologic signs 
Brain tumor or abscess, 
AVM; Stroke; CVT; CNS 
Vasculitis 
Neuroimaging including 
MRV, lumbar puncture, 
blood tests for 
autoantibodies 
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Table 2: The triptans 
 
Drug Route Dose Max dose per day Comments 
Oral 50 mg 
100 mg 
200 mg 
 
The triptan that has 
been used for the 
longest period of 
time  
 
Nasal spray 5 mg 
20 mg 
40 mg More rapid onset of 
action then the oral 
formulation 
Sumatriptan 
Injection (s.c.) 6 mg 12 mg Most rapid onset of 
action; highest 
efficacy 
Oral 2.5  mg 
5 mg 
Zolmitriptan 
Orally-
dissolved  
2.5  mg 
5 mg 
10 mg 
 
Efficacy and 
tolerability similar 
to sumatriptan 
 
Oral 5 mg 
10 mg 
Rizatriptan 
Orally-
dissolved 
5 mg 
10 mg 
30 mg  
 
Reduce dose by 
50% when taken 
with propranolol 
 
Naratriptan Oral 1 mg 
2.5 mg 
5 mg 
 
Long half life (6h); 
few adverse events 
 
Almotriptan Oral 6.25 mg 
12.5 mg 
25 mg 
 
Efficacy similar to 
sumatriptan, slightly 
better tolerability 
Frovatriptan Oral 2.5 mg 7.5 mg Longest half life 
(25h) 
 
Eletriptan Oral 20 mg 
40 mg 
80 mg 
 
High bioavailability 
and efficacy 
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Table 3: Preventive drug treatment for migraine 
Abbreviations: CHF – congestive heart failure; PVD – peripheral vascular disease; DM – 
diabetes mellitus 
 
Drug  group Drug  Daily dose Side effects Contraindications/
comments 
Propranolol 80-240 mg -adrenergic 
blockers 
 Metoprolol 100-200 mg 
Fatigue, sleep 
disorders, 
impotence, 
depression, 
orthostatic 
symptoms 
Asthma, CHF, 
PVD, DM 
Amitriptyline 10-75 mg Sedation, weight 
gain, dry mouth 
Urinary retention, 
mania 
Fluoxetine 10-80 mg Anxiety, 
insomnia, 
sexual  
dysfunction 
mania 
Antidepressants 
Phenelzine 30-90 mg Insomnia, weight 
gain, peripheral 
edema 
Concomitant 
sympathomimetic 
drugs; avoid 
tyramine- 
containing foods 
Divalproex 
sodium  
800-1200 mg Sedation, tremor, 
alopecia, weight 
gain, 
hepatotoxicity 
Liver disease, 
pregnancy, 
hematologic 
disorders 
Anticonvulsants
Topiramate 100-400 mg Paresthesias, 
fatigue, weight 
loss, cognitive 
impairment 
Renal stones 
Flunarizine 5-15 mg Fatigue, weight 
gain, depression, 
parkinsonism 
Extra-pyramidal 
disorders 
Calcium 
channel 
blockers 
Verapamil 160-320 mg  Constipation, 
peripheral edema 
Heart block, 
hypotension 
Serotonin 
antagonists 
Methysergide 1-6 mg Myalgia, nausea, 
weight gain, 
fibrosis 
Stop treatment 
every 6 months for 
4 weeks.  
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Table 4: Pharmacologic treatment of cluster headache 
AEs – adverse events 
 
Treatment 
type 
Drug Route Dose Comments 
Oxygen 100% Non-
rebreathing 
mask 
>7 L/min for 
15 min 
Effective but not 
always readily  
available 
Sumatriptan Injectable 
(s.c.) 
6 mg Very effective 
Acute  
Dihydroergotamine Injectable 
(i.v.) 
1 mg Not available at 
home 
Prednisone oral 60 mg/day, 
taper 
gradually 
Multiple potential 
AEs 
Preventive-
transitional  
Ergotamine oral 2 mg/day Can not be given 
with triptans 
Verapamil oral 240-720 
mg/day 
Monitor ECG  
Lithium carbonate oral 600-900 
mg/day 
Monitor drug 
levels, kidney and 
thyroid functions 
Methysergide oral 2-12 mg/day Can not be used 
with ergots  
Valproic acid oral 500-2000 
mg/day 
Monitor drug blood 
levels, LFTs and 
CBC 
Topiramate oral 50-125 
mg/day 
Potential cognitive 
AEs and renal 
calculi 
Preventive-
maintenance 
Melatonin oral 10 mg Few AEs 
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Appendix 1:  IHS diagnostic criteria for migraine without aura  
1.1 Migraine without aura 
A. At least 5 attacks fulfilling criteria B-D 
B. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated) 
C. Headache has at least two of the following characteristics: 
1. unilateral location 
2. pulsating quality 
3. moderate or severe pain intensity 
4. aggravation by or causing avoidance of routine physical activity (eg,
walking or climbing stairs) 
D. During headache at least one of the following: 
1. nausea and/or vomiting 
2. photophobia and phonophobia 
E. Not attributed to another disorder 
 
Appendix 2: IHS diagnostic crieteria for migraine with aura  
1.2 Migraine with aura 
A. At least 2 attacks fulfilling criterion B 
B. Migraine aura fulfilling criteria B and C for one of the subforms 1.2.1-1.2.6 
C. Not attributed to another disorder 
 
1.2.1 Typical aura with migraine headache 
 
A. At least 2 attacks fulfilling criteria B–D 
B. Aura consisting of at least one of the following, but no motor weakness: 
1. fully reversible visual symptoms including positive features (eg, flickering 
lights, spots or lines) and/or negative features (ie, loss of vision) 
2. fully reversible sensory symptoms including positive features (ie, pins and 
needles) and/or negative features (ie, numbness) 
3. fully reversible dysphasic speech disturbance 
C. At least two of the following: 
1. homonymous visual symptoms and/or unilateral sensory symptoms 
2.  at least one aura symptom develops gradually over 5 minutes and/or 
different aura symptoms occur in succession over 5 minutes 
3. each symptom lasts 5 and 60 minutes 
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D. Headache fulfilling criteria B-D for 1.1 Migraine without aura begins during the 
aura or follows aura within 60 minutes 
E. Not attributed to another disorder 
 
Appendix 3:  IHS diagnostic criteria for cluster headache 
3.1 Cluster headache 
A. At least 5 attacks fulfilling criteria B-D 
B. Severe or very severe unilateral orbital, supraorbital and/or temporal pain lasting 15-
180 minutes if untreated 
C.  Headache is accompanied by at least one of the following: 
1. ipsilateral conjunctival injection and/or lacrimation 
2. ipsilateral nasal congestion and/or rhinorrhoea 
3.  ipsilateral eyelid oedema 
4. ipsilateral forehead and facial sweating 
5. ipsilateral miosis and/or ptosis 
6. a sense of restlessness or agitation 
D.  Attacks have a frequency from one every other day to 8 per day 
E.   Not attributed to another disorder 
 
Appendix 4: IHS diagnostic criteria for chronic tension-type headache  
2.3 Chronic tension-type headache 
A. Headache occurring on 15 days per month on average for >3 months (180 days 
per year) and fulfilling criteria B-D 
B. Headache lasts hours or may be continuous 
C. Headache has at least two of the following characteristics: 
1.  bilateral location 
2.  pressing/tightening (non-pulsating) quality 
3. mild or moderate intensity 
4. not aggravated by routine physical activity such as walking or climbing 
stairs 
D. Both of the following: 
1. no more than one of photophobia, phonophobia or mild nausea 
2. neither moderate or severe nausea nor vomiting 
E. Not attributed to another disorder 
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Appendix 5: IHS diagnostic criteria for cervicogenic headache 
11.2.1 Cervicogenic headache 
 
A.  Pain, referred from a source in the neck and perceived in one or more regions of 
the head and/or face, fulfilling criteria C and D 
B. Clinical, laboratory and/or imaging evidence of a disorder or lesion within the 
cervical spine or soft tissues of the neck known to be, or generally accepted as, a 
valid cause of headache 
C. Evidence that the pain can be attributed to the neck disorder or lesion based on at 
least one of the following: 
1.  demonstration of clinical signs that implicate a source of pain in the neck2
2.  abolition of headache following diagnostic blockade of a cervical structure 
or its nerve supply using placebo- or other adequate controls3
D.  Pain resolves within 3 months after successful treatment of the causative disorder 
or lesion 
 
Appendix 6:  The Cervicogenic Headache International Study Group diagnostic criteria 
for cervicogenic headache                       
 
I. Symptoms and signs of neck involvement: 
a. precipitation of head pain similar to the usually occurring one: 
 1. by neck movement and/or sustained awkward head positioning, and/or 
2. by external pressure over the upper cervical or occipital region on the 
symptomatic side 
b. restriction of the range of motion (ROM) in the neck 
c. ipsilateral neck, shoulder or arm pain of a rather vague nonradicular nature or 
occasionally arm pain of a radicular nature 
 
II. Confirmatory evidence by diagnostic anesthetic blockades 
 
III. Unilaterality of the head pain, without side shift 
 
